The financial terms of the deal were not disclosed.
Bioscreen, which launched in 2005, manufactures encapsulates and fermented products targeted at animal nutrition and health.
The US company said Bioscreen's existing business will be integrated within Balchem's animal nutrition and health business segment, which has a focus on encapsulated nutrients, choline products and chelated minerals.
Jonathan Griffin, VP and general manager of Balchem’s animal nutrition and health division said while Bioscreen does not bring significant existing business to Balchem, this acquisition provides a European manufacturing platform for the New York based company’s encapsulated nutrients and will allow it to accelerate its growth within Europe.
“The addition of local European manufacturing capabilities for our encapsulated products, to our existing European choline manufacturing footprint, further strengthens our ability to bring a broad range of health and nutrition solutions to our European customers."
Balchem financial results
In its Q2 results released in early August, Balchem reported that its animal nutrition and health segment recorded sales of $42m, which was an increase of $5m or 13.5% compared to the prior year quarter:
“The increased sales were primarily due to higher monogastric species sales, driven by healthy demand in North America and Europe, higher average selling prices, and additional sales realized as a result of the continuing supply disruptions of Chinese imports, partially offset by lower ruminant species sales.
It said second quarter earnings from operations for this segment of $7.1m were $3.4m or 92.8% higher than the prior year comparable quarter of $3.7m, primarily due to those higher monogastric sales volumes and higher average selling prices.